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11 ABSTRACT: Macrocyclic monoacyl lathyrane derivatives bearing a benzoyl moiety were previously found to be strong ABCB1
12 modulators. To explore the eﬀects of diﬀerent substituents of the aromatic moiety, 14 new compounds (1.1−1.7, 1.10, and 2.1−
13 2.4) were prepared from jolkinol D (1), obtained from Euphorbia piscatoria, and from jolkinodiol (2), its hydrolysis derivative.
14 Compounds 1.8 and 1.9, having aliphatic moieties, were also obtained. The reversal of ABCB1-mediated MDR was evaluated
15 through functional and chemosensitivity assays on the human ABCB1-gene-transfected L5178Y mouse T-lymphoma cell line.
16 Structure−activity relationships showed that addition of electron-donating groups to the aromatic moiety improved the activity.
17 The eﬀects on the ATPase activity of the strongest modulator (1.3) and the inactive jolkinol D (1) were also investigated and
18 compared. Moreover, in the chemosensitivity assay, most of the compounds interacted synergistically with doxorubicin.
19 Compounds 1.1−1.10 and 2.1−2.4 were further assessed for their collateral sensitivity eﬀect against the human cancer cells:
20 EPG85−257 (gastric) and EPP85−181 (pancreatic), and the matching drug-selected cells EPG85-257RDB, EPG85-257RNOV,
21 EPP85-181RDB, and EPP85-181RNOV. The most promising ones (1.8 and 1.10) along with compound 3, previously selected,
22 were investigated as apoptosis inducers. The compounds were able to induce apoptosis through caspase-3 activation, with
23 signiﬁcant diﬀerences being observed between the parental and resistant cells.
24 Throughout the world, cancer continues to be a leading25 cause of mortality.1 Despite the number of advances in
26 this ﬁeld, the development of resistance to anticancer drugs
27 constitutes one of the main problems for a successful treatment.
28 In the course of chemotherapy, multidrug resistance (MDR) is
29 likely to occur, and as a result, tumors fail to respond to a broad
30 spectrum of structurally and mechanistically diverse anticancer
31 agents.2,3 A panoply of cellular resistance mechanisms related
32 with an MDR cancer phenotype have been identiﬁed; one of
33 the most widely studied involves the transmembrane ABC
34 transporter P-glycoprotein (P-gp/ABCB1).4−6 In normal cells,
35 this eﬄux pump takes part in the natural detoxifying system,
36 recognizing xenobiotics and extruding them from the cytosol.
37 However, in cancer cells, ABCB1 overexpression causes a
38 reduction of the cytosolic concentration of the anticancer agent.
39 This will lead to a treatment failure resulting in cross-resistance
40to several cytotoxic drugs, such as cisplatin, colchicine,
41vinblastine, paclitaxel, doxorubicin, and protein kinase inhib-
42itors.6 The improvement of chemotherapies targeted to
43overcome cancer MDR holds promise for a selective and
44eﬃcient cancer treatment. Promising strategies to accomplish
45that purpose depend on the research of molecules capable of
46lessening the ABCB1 drug eﬄux, and the discovery of
47compounds with collateral sensitivity activity.7,8
48The collateral sensitivity eﬀect was ﬁrst observed in bacteria,
49but nowadays it is being used as a powerful asset to study
50cancer MDR.8,9 In resistant cancer cells, each genomic,
51proteomic, or metabolomic alteration that conferred advantages
52during chemotherapeutic pressure might be at the same time a
Received: November 21, 2016
Article
pubs.acs.org/jnp
© XXXX American Chemical Society and
American Society of Pharmacognosy A DOI: 10.1021/acs.jnatprod.6b01084
J. Nat. Prod. XXXX, XXX, XXX−XXX
amm00 | ACSJCA | JCA10.0.1465/W Unicode | research.3f (R3.6.i12 HF02:4458 | 2.0 alpha 39) 2016/10/28 09:46:00 | PROD-JCAVA | rq_8451873 | 4/13/2017 09:28:14 | 10 | JCA-DEFAULT
53 way to create vulnerabilities. The collateral sensitivity eﬀect
54 approach takes advantage of these vulnerabilities, converting
55 them into new therapeutic targets.8,10,11 Consequently, drug-
56 resistant phenotypes can be more sensitive to alternate agents
57 than the original parental cell line.8,11 As a result, highly
58 selective compounds can be found and characterized.
59 Anticancer drug discovery programs are increasing their
60 interest in natural products.12 Nature presents a vast chemical
61 space that was selected through evolution to interact with a
62 wide range of biological targets. Therefore, it is not surprising
63 why natural compounds and their derivatives have become
64 eﬀective anticancer drugs.13 Owing to the fast pace of
65 development of drug resistance, a growing chemical space is
66 needed. In this regard, Euphorbia macrocyclic diterpenoids of
67 the jatrophane- and lathyrane-type have shown signiﬁcant
68 MDR reversal activity, by ABCB1 modulation and/or by
69 selective targeting of MDR cancer cells. These promising
70 results guide us to the development of in silico studies, and
71 structure activity studies for optimizing their structures in order
72 to develop an eﬀective MDR reversal agent.14−19 Despite this
73 progress, understanding their anti-MDR mode of action is still
74 lacking.
75 In a previous report, we discussed a small library of jolkinol
76 D derivatives in order to study the impact of structural
77 modiﬁcations on ABCB1 eﬄux modulation. It was concluded
78 that the presence of an aromatic moiety improved the
79 inhibition of this eﬄux pump at noncytotoxic doses.20
80 Moreover, these derivatives were evaluated for their collateral
f1 81 sensitivity eﬀects, of which jolkinoate L (3, Figure 1) displayed
82 an interesting MDR-selective antiproliferative activity.21 In the
83 sequence of this anti-MDR development project, we optimized
84 jolkinol D (1) and jolkinodiol (2) scaﬀolds by generating a new
85 set of derivatives (1.1−1.10 and 2.1−2.4) in order to obtain a
86 higher MDR reversal eﬀect. This was assessed through the
87 combination of ABCB1 modulation and collateral sensitivity
88 eﬀects. Thus, compounds 1.1−1.10 and 2.1−2.4 were tested
89 for their ability to modulate the drug eﬄux activity of ABCB1
90 and to resensitize MDR cells to doxorubicin in drug
91 combination studies, using MDR1-transfected mouse T-
92 lymphoma L5178Y cells. The type of interaction with the
93 ATPase function of ABCB1 was also investigated for the parent
94 molecule (1) and the strongest modulator (1.3). The MDR-
95 selective antiproliferative activity was assayed using the human
96 tumor gastric (EPG85-257) and pancreatic (EPP85-181) cell
97 models (drug-sensitive and drug-resistant sublines), well
98 characterized for MDR.21−23 The most promising derivatives
99 (1.8, 1.10), and jolkinoate L (3), were investigated for their
100 potential as apoptosis inducers.
101■ RESULTS AND DISCUSSION
102Chemistry. The previous structure−activity relationship
103(SAR) analysis of jolkinol D (1) derivatives showed that
104ABCB1 eﬄux modulation was enhanced when an aromatic
105ester moiety was added to the lathyrane scaﬀold.20 However,
106the role of aromatic electronic eﬀects as well as hindrance
107eﬀects on ABCB1 eﬄux activity was still to be investigated. As a
108result, a new set of derivatives (1.1−1.10 and 2.1−2.4) was
109generated. Jolkinoates J−T (1.1−1.7) were obtained by
110reaction of jolkinol D (1), isolated from Euphorbia piscatoria
111Ait. (Euphorbiacae),20 with the respective aroyl chlorides in the
112 s1presence of CH2Cl2, TEA, and DMAP (Scheme 1). In parallel,
113to study the role of the free hydroxy group at C-15, jolkinolates
114A−D (2.1−2.4) were prepared using jolkinodiol (2)20 as
115parent molecule (Scheme 1). Moreover, an adamantane
116derivative (1.8) and two carbonate esters, one aliphatic (1.9)
117 s2and one aromatic (1.10), were also synthesized (Scheme 2),
118using silver triﬂate24 as catalyst. The structures of the
119derivatives were assigned by 1D and 2D NMR and HRMS
120data. The 1H and 13C NMR data of compounds 1.1−1.10 and
1212.1−2.4 were compared with those of jolkinol D (1) and
122jolkinodiol (2), respectively. As expected, the main diﬀerences
123were found for C-3 and H-3, which showed paramagnetic
124eﬀects in carbon and proton chemical shifts (ΔδC ≅ 0.2−6.4
125and ΔδH ≅ 1.1−1.9 ppm), due to the presence of the ester
126function. The β-carbons of the acyl derivatives (C-2 and C-4)
127also showed the anticipated diamagnetic eﬀects (ΔδC ≅ 0.8
128and 0.6−1.4 ppm, respectively).
129ABCB1-MDR Reversal Activity. In order to compare with
130the previous results, the same experimental design20 was
131followed. The antiproliferative activity of the compounds was
132assayed against the parental mouse T-lymphoma cells (L5178Y-
133PAR), and the ABCB1-transfected counterpart (L5178Y-
134MDR), using the MTT assay. The derivatives 1.1−1.10 and
1352.1−2.4 did not show a signiﬁcant antiproliferative proﬁle (IC50
136> 19 μM) for both cell lines (Table S1).
137Modulation of ABCB1 eﬄux was tested using the standard
138rhodamine-123 functional assay. Whether a compound
139modulates ABCB1 eﬄux or not is given by the ﬂuorescence
140activity ratio (FAR). This ratio represents the accumulation of
141rhodamine-123 between L5178Y-MDR and L5178Y-PAR cells.
142Modulation of ABCB1 is considered to occur when FAR values
143are higher than one. Strong modulation of this transporter
144occurs when this ratio is higher than 10.25 The derivatives 1.1−
1451.10 and 2.1−2.4 were tested at 2 and 20 μM (nontoxic
146concentrations), and verapamil, a standard modulator, was used
147as positive control. When tested at 20 μM, all the lathyrane
148derivatives (1.1−1.10; 2.1−2.4) caused a strong impairment of
149ABCB1 eﬄux activity, with FAR values ranging from 9.9 to 41.5
150 t1(Table 1). The strongest modulators of this library were
151depicted based on the 2 μM data (Table 1). Thus, the most
152eﬃcient modulators were the jolkinol D derivatives 1.2, 1.3,
1531.5−1.8, and 1.10 and the jolkinoldiol derivative 2.1 (FAR
154values from 10.8 to 33.3). These results are interesting because
155the ABCB1 reversal activity of verapamil (22 μM) was 12.5.
156Structure−Activity Relationships. The K-means cluster-
157ing algorithm was used to highlight some of the possible
158relations between ABCB1 modulatory activity and the
159calculated physicochemical features. As a result, four groups
160sharing a high degree of similarity, in terms of physicochemical
161 f2properties and activity at 2 μM, were generated (Figure 2). The
162ﬁrst cluster grouped the derivatives with the bulkier
Figure 1. Jolkinoate L (3).
Journal of Natural Products Article
DOI: 10.1021/acs.jnatprod.6b01084
J. Nat. Prod. XXXX, XXX, XXX−XXX
B
163 substituents (1.4, 1.6, 1.7, 1.8, and 2.4), therefore showing the
164 highest MW, MV, logP, MR, and ASA values (Figure 2). The
165 strongest ABCB1 modulators 1.2, 1.3, and 1.5 were grouped
166 mainly due to the FAR values, since their physicochemical
167 properties are shared by compounds in clusters I and III
168 (Figure 2). Cluster III comprised the jolkinodiol derivatives
169 2.1−2.3 as well as compounds 1.1 and 1.10. Jolkinocarbonate
170 A (1.9) occupied cluster IV. Nevertheless, contrary to what was
171 described for the ﬁrst set of jolkinol D derivatives,20 no
172 signiﬁcant correlations were found between the computed
173 physicochemical properties and ABCB1 modulatory activity.
174 This can be suggestive of a stronger role of the sum of other
175 structural aspects, than the contribution of a single
176physicochemical property. In fact, a recent in silico study,
177through 2D and 3D Q(quantitative)SAR, concluded that the
178conformation of the lathyrane macrocyclic scaﬀold and its
179substitution pattern (related to steric and electrostatic factors)
180were the main determinants for the ABCB1 modulation
181activity.19
182Therefore, to investigate the former observations, attention
183was focused on the SAR of esters containing the aromatic
184moiety; in this way, we compared the previous results20 with
185those described herein. Thus, in comparison to jolkinoate I,20
186bearing an unsubstituted aroyl moiety (FAR = 24.2), the
187introduction of triﬂuormethyl, an electron-withdrawing group,
188at the meta or para positions of the benzene moiety, lead to a
Scheme 1. Preparation of Jolkinoates N−T (1.1−1.7) and Jolkinolates A−D (2.1−2.4)a
aReagents and conditions: 1 equiv of jolkinol D (1); 1 equiv of jolkinodiol (2); (i) Respective aroyl chlorides; TEA, CH2Cl2, DMAP (cat.), reﬂux 60
°C.
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Scheme 2. Preparation of Jolkinoate U (1.8) and Jolkinocarbonates A and B (1.9−1.10)a
aReagents and conditions: 1 equiv of jolkinol D (1); (a) Respective chlorides; AgOTF (1 mol %), CH2Cl2, reﬂux 60 °C.
Table 1. Modulation of ABCB1-Mediated Rhodamine-123 Eﬄux by Jolkinol D Derivatives 1.1−1-10 and Jolkinodiol
Derivatives 2.1−2.4
aFAR = (L5178Y-MDRFL‑1treated/L5178Y-MDRFL‑1control)/(L5178Y-PARFL‑1treated/L5178Y-PARFL‑1control). FL-1: mean ﬂuorescence intensity of the
cells. Verapamil (22 μM) FAR = 12.5. DMSO (2%) FAR = 0.87.
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189 decreased eﬄux modulatory eﬃciency [(2.5-fold) FAR = 9.3
190 and 9.4, respectively to jolkinoate L20 and 1.4]. Likewise,
191 jolkinocarbonate B (1.10; FAR = 10.8) with a phenyl
192 substituent, lost modulatory ability in comparison to jolkinoate
193 I. Jolkinoate N (1.1; FAR = 2.2), displaying an m-methyl group,
194 was nearly inactive. However, jolkinoate J,20 possessing this
195 moderate electron-donating group at the para position, retained
196 a strong modulatory character (FAR = 21.1). The eﬀects of a
197 strong electron-donating group were investigated by using the
198 methoxy group; nevertheless, diﬀerences in activity were not
199 signiﬁcant. Incorporation of this group at the ortho (1.3; FAR =
200 33.3) and para (jolkinoate K; FAR = 28.1)20 positions seemed
201 to have a slightly higher electronic inﬂuence due to the
202 resonance eﬀects than its regioisomer at the meta position (1.2;
203 FAR = 26.1). Moreover, jolkinoate R (1.5; FAR = 28.6),
204 bearing a cinnamoyl moiety, was also among the strongest
205 modulators, suggesting that the aromatic conjugated system is a
206 contributor toward ABCB1 modulation.
207The potential steric hindrance on ABCB1 eﬄux modulation
208was studied by inclusion of bulky groups such as naphthoyl
209(1.6; FAR = 11.9), biphenoyl (1.7; FAR = 11.6), and
210adamantoyl (1.8; FAR = 12.6). The 2-fold reduction of
211modulatory eﬃciency, when compared to jolkinoate I (FAR =
21224.2),20 suggests that introduction of a bicyclic moiety
213potentiates steric clashes within the drug-binding pocket of
214ABCB1, independently from its aromatic nature. Similar
215observations were found by Jiao and co-workers, which veriﬁed
216that lathyrol derivatives with 1-naphthylacetyl or phenylacetyl
217substituents lost ABCB1 modulatory ability.26
218Furthermore, some derivatives of jolkinodiol (2) were
219included to test the role of a free hydroxy group at C-15.
220Jolkinolate A (2.1), bearing a 3-methoxybenzoyl moiety at C-3,
221showed a 2-fold loss in eﬃcacy in comparison to jolkinoate O
222(1.2), where the hydroxy group at C-15 is acetylated. The same
223tendency was observed for the jolkinoldiol derivatives 2.2, 2.3,
224and 2.4 in comparison to their respective counterparts 1.4, 1.6,
Figure 2. Cluster analysis of compounds 1.1−1.10 and 2.1−2.4. Box and whiskers plot representing each grouping variable: FAR values (2 μM),
molecular weight (MW), molecular volume (MV), logP prediction developed at Molinspiration (logP), molar refractivity (MR), topological polar
surface area (TPSA), and accessible solvent area (ASA). Physicochemical properties were calculated using JME molecular editor, version July 2016,
http://www.molinspiration.com/jme.
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225 and 1.7 (Table 1). Thus, the presence of the acetyl group at C-
226 15 as a hydrophobic center or hydrogen-bond acceptor moiety
227 might be more important for recognition/interaction with
228 ABCB1 than the presence of a hydrogen-bond donor. These
229 ﬁndings are in accordance with the in-house pharmacophore
230 model, based on macrocyclic diterpenoids and other ABCB1
231 inhibitors, in which the recognition pattern contains three
232 hydrophobic moieties and one hydrogen-bond acceptor
233 group.14
234 In conclusion, with this SAR study a favorable optimization
235 for jolkinoates as ABCB1 modulators was achieved. Benzoyl
236 moieties with electron-donating groups should increase the
237 electrostatic interactions and π-stacking at the drug-binding
238 pocket of ABCB1, resulting in a more powerful ABCB1 eﬄux
239 modulation.
240 Eﬀects on the ATPase Activity of ABCB1. ATP
241 hydrolysis is linked with the ABCB1 eﬄux activity.27,28 The
242 way how compounds aﬀect this catalytic activity can give
243 insights about their properties as substrate or inhibitor.
244 Therefore, the eﬀects on the ATPase activity of this membrane
245 transporter were evaluated for the parent compound jolkinol D
246 (1) and the most active modulator of this set of lathyranes,
247 jolkinoate P (1.3). This activity was assessed through the
248 production of inorganic phosphate directly resulting from the
249 ATP hydrolysis of human ABCB1 expressed in puriﬁed insect
250 membrane vesicles (Sf9). Vanadate is a phosphate analogue
251 that inhibits ABCB1 ATPase activity; therefore, the results
252 obtained are presented as the vanadate sensitive ATPase
253 activity. This ATPase experiment is composed of two
254 complementary assays. The activation assay classiﬁes com-
255 pounds as stimulators or inhibitors of the baseline vanadate
256 sensitive ATPase activity. The inhibition assay, performed in
257 the presence of a known ABCB1 activator, is used to
258 characterize eﬄux inhibitors (or slowly transported substrates)
259 through the decrease of verapamil-stimulated vanadate-sensitive
260 ATPase activity. Verapamil (40 μM) and cyclosporin A (40
261 μM) were used as positive controls in the activation and
262 inhibition assays, respectively. Jolkinol D (1) and jolkinoate P
263 (1.3) were tested in a dose-dependent manner, and the eﬀects
264 were shown as the relative ATPase activity, in which the
265 stimulated vanadate-sensitive ATPase activity is taken as 100%
266 and the baseline vanadate-sensitive ATPase activity as 0%.
267 Jolkinol D (1) enhanced the basal ATPase activity with 66−
f3 268 87%, though this stimulation was not dose dependent (Figure
f3 269 3A, activation assay). These ﬁndings indicate that compound 1
270 interacts with the membrane transporter ABCB1. Concerning
271 the verapamil-stimulated ATPase activity, jolkinol D (1)
272 showed an inhibitory eﬀect of 14−40%, in the range 3.13−
273 12.5 μM (Figure 3A, inhibition assay). At higher concentrations
274 (25−100 μM), compound (1) showed 9−33% stimulation of
275 the verapamil-stimulated ATPase activity (Figure 3A, inhibition
276 assay). The results from this ATPase assay suggest jolkinol D
277 (1) to be a transported substrate of ABCB1, which at some
278 concentrations can aﬀect verapamil transport (inhibition or
279 stimulation). Nevertheless, it should be noted that jolkinol D
280 (1) did not aﬀect ABCB1 eﬄux at 2 or 20 μM.20
281 Interesting results were obtained with the strong modulator
282 jolkinoate P (1.3). The direct interaction with ABCB1 is shown
283 through the activation of the ATPase activity (Figure 3B,
284 activation assay). This activation occurred to a lower extent
285 compared to jolkinol D (1). Moreover, at higher doses (>50
286 μM), jolkinoate P (1.3) inhibited ABCB1 ATPase activity. This
287 type of dose-dependent activation of ATPase activity at low
288concentrations and inhibition at higher concentrations was
289observed for several compounds.29,30 Recently, a conforma-
290tionally gated model of drug-induced activation of ABCB1-
291mediated ATP hydrolysis was established to study this issue.30
292According to this model, when verapamil occupies the H-site of
293the ABCB1 drug-binding pocket, ATP hydrolysis and transport
294are maximized at low concentrations of verapamil. When
295verapamil is present in high concentrations, it occupies both the
296H-site and a low aﬃnity binding site; due to this, the protein is
297stabilized into an “intermediate” conformation that prevents
298ATP from driving ABCB1 to the ‘‘closed” conformation.
299Consequently, the verapamil transport and verapamil-stimu-
300lated ATP hydrolysis are reduced. These ﬁndings might help to
301understand the jolkinoate P (1.3) dose eﬀect on the ABCB1
302ATPase activity.
303When tested concomitantly with a second substrate,
304jolkinoate P (1.3) was able to diminish the verapamil-
305stimulated ATPase activity, with a complete inhibition at 1.56
306and 25 μM (Figure 3B, inhibition assay). This indicated that
307jolkinoate P (1.3) was capable of ceasing the transport of
308verapamil, through direct interaction with ABCB1. Moreover,
309the inhibition assay also suggested jolkinoate P (1.3) to elicit a
310biphasic dose response on the ABCB1 ATPase. This biphasic
311nature was observed for some compounds and might be
312attributed to the polyspeciﬁcity of ABCB1 drug-binding sites.31
313Verapamil and rhodamine-123 have diﬀerent binding sites
314within the drug-binding pocket of ABCB1.32,33 Relating the
315results obtained in this work, it can be suggested that
316compound 1.3 might act as a modulator and/or a slowly
Figure 3. Eﬀects of (A) jolkinol D (1) and (B) jolkinoate P (1.3) on
ABCB1 ATPase activity. Activation assay: tests the eﬀect on the basal
ATPase activity. Inhibition assay: tests the eﬀect on drug-stimulated
ATPase activity, measured in the presence of verapamil (40 μM).
Results are expressed as the mean ± SD. The eﬀects of compounds are
shown as the relative ATPase activity, in which the verapamil-
stimulated vanadate-sensitive ATPase activity is taken as 100% and the
baseline vanadate-sensitive ATPase activity as 0%.
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317 transported substrate aﬀecting the transport of these two
318 molecules.
319 Chemosensitization: Reversion of Drug-Induced Re-
320 sistance. In order to test if the lathyrane derivatives would
321 turn L5178Y-MDR cells more susceptible to anticancer drug
322 action, their combinations with doxorubicin were tested. The
323 nature of the drug interactions was determined by the
324 combination index (CI) as synergistic, additive, or antagonistic
t2 325 (Table 2).34,35 Apart from jolkinoates R (1.5) and U (1.8), and
326 jolkinocarbonate A (1.9), that showed an antagonistic eﬀect on
327 the combination assay (CI = 1.11−2.02, Table 2), the
328 remaining derivatives improved the cytotoxicity of doxorubicin
329 synergistically (CI = 0.20−0.84). The modulators were able to
330 restore sensitivity to doxorubicin by reversing the ABCB1-
331 MDR phenotype.
332 Collectively the results from the transport (Table 1) and
333 drug combination assays (Table 2) showed that the tested
334 resistance modulators were able to aﬀect ABCB1 eﬄux activity
335 and to restore sensitivity to doxorubicin (except compounds
336 1.5, 1.8, and 1.9). This is an interesting ﬁnding because the
337 cytotoxic eﬃcacy of doxorubicin is known to be aﬀected by
338 ABCB1 activity.6,36 Moreover, it is interesting to note that,
339 although jolkinoates R (1.5) and U (1.8) were strong ABCB1
340 modulators at 2 μM, they displayed antagonistic eﬀects in the
341 combination experiments. These compounds might be
342 targeting other cellular pathways and, thus, may antagonize
343 the doxorubicin eﬀect by competing or inhibiting its targets,
344 independently from interaction with ABCB1.
345 Conversely, jolkinol D (1), a non-ABCB1 modulator,
346 showed a synergistic eﬀect with doxorubicin.20 Recalling the
347 nature of interaction with ATPase, jolkinol D (1) was qualiﬁed
348 as a transported substrate, and this result might contribute to
349 explaining why the combination between this nonmodulator
350 and the cytotoxic drug showed a synergistic nature.20
351 Therefore, this compound might have more aﬃnity or compete
352 with doxorubicin for ABCB1 transport, suggesting accumu-
353 lation of doxorubicin to the detriment of jolkinol D (1) eﬄux.
354Collateral Sensitivity Eﬀect. In a preceding study, some
355jolkinol D derivatives were assessed for their potential selective
356antiproliferative activity against parental gastric (EPG85-257)
357and pancreatic (EPP85-181) human cancer cells and their drug-
358resistant counterparts, selected against mitoxantrone (RNOV)
359or daunorubicin (RDB), respectively, using a proliferation
360assay.21 Most of those derivatives exhibited selective anti-
361proliferative activity eﬀects toward the EPG85-257RDB cell
362line. However, jolkinoate L (3) showed a remarkable ability to
363target diﬀerent cellular contexts with concomitant high
364antiproliferative activity.21 As a continuation of this develop-
365ment program, herein compounds 1.1−1.10 and 2.1−2.4 were
366investigated for their potential collateral sensitivity eﬀect on the
367same cancer entities (Tables S2 and S3, Supporting
368Information).
369The MDR-selective activity was assessed by the relative
370resistance ratio (RR = IC50(resistant)/IC50(parental)). RR < 1
371indicates that the compound kills MDR cells more eﬀectively
372than parental cells, but if RR < 0.5, a collateral sensitivity eﬀect
373is taking place.10 The cytotoxic agents etoposide and cisplatin
374were used as positive controls. The antiproliferative activity and
375collateral sensitivity eﬀects of compounds 1.1−1.10 and 2.1−
376 t32.4 are shown as a heat map table (Table 3). This
377representation enables the identiﬁcation of compounds that
378show MDR-selective activity at a determined IC50 level. Most of
379the derivatives were highly eﬀective toward the resistant gastric
380cell lines, exhibiting an antiproliferative activity comparable to
381the positive controls cisplatin and etoposide (Table 3, Table S2,
382Supporting Information). The collateral sensitivity eﬀect (RR ≤
3830.5) was mostly observed for EPG85-257RDB cells, which are
384characterized by ABCB1 overexpression.37 With respect to
385EPG85-257RNOV cells, the best results were obtained for
Table 2. Drug Combination Experiments in ABCB1-
Transfected Mouse T-Lymphoma Cells (L5178Y-MDR)
Combination with
Doxorubicin Ratioa CI ± SDb Interaction
Jolkinoate O (1.2) 25:1 0.84 ± 0.14 moderate synergism
Jolkinoate P (1.3) 10:1 0.09 ± 0.03 very strong
synergism
Jolkinoate R (1.5) 50:1 1.13 ± 0.37 slight antagonism
Jolkinoate S (1.6) 400:1 0.06 ± 0.02 very strong
synergism
Jolkinoate T (1.7) 100:1 0.32 ± 0.08 synergism
Jolkinoate U (1.8) 15:1 1.11 ± 0.37 slight antagonism
Jolkinocarbonate A (1.9) 5:1 1.22 ± 0.28 moderate
antagonism
Jolkinocarbonate B (1.10) 18:1 0.50 ± 0.07 synergism
Jolkinolate A (2.1) 50:1 0.38 ± 0.16 synergism
Jolkinolate C (2.3) 200:1 0.20 ± 0.05 strong synergism
aData are shown as the best combination ratio of the tested
compounds and doxorubicin. bCombination index (CI) values are
mean ± standard deviation (SD) for an inhibitory concentration of
50% (IC50). CI < 0.1: very strong synergism; 0.1 < CI < 0.3: strong
synergism; 0.3 < CI < 0.7: synergism; 0.7 < CI < 0.9: moderate to
slight synergism; 0.9 < CI < 1.1: nearly additive; 1.10 < CI < 1.45:
moderate antagonism; 1.45 < CI < 3.30: antagonism.34,35 Compounds
1.1, 1.4, 2.2, and 2.4 are not assayed due to IC50 > 80 μM.
Table 3. Heat Map Table Summarizing the Antiproliferative
and Collateral Sensitivity Results against Gastric Carcinoma
Cells (EPG85-257P, EPG85-257RNOV, and EPG85-
257RDB) and Pancreatic Carcinoma Cells (EPP85-181P,
EPP85-181RNOV, and EPP85-181RDB)a
aThis representation permits identifying compounds that show MDR-
selective activity at a determined IC50 sevel. Collateral sensitivity values
(RR < 0.5) are shown.
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386 compounds 1.1, 1.4, 1.8, 1.9, 1.10, and 2.3, which showed IC50
387 values lower than 10 μM (Table 3, Table S2), but only
388 derivatives 1.4 and 2.3 showed a collateral sensitivity eﬀect (RR
389 < 0.5). Nevertheless, no structure−activity relationships could
390 be inferred for these cell lines. Based on the IC50 and RR values
391 (Table 3, Table S2), jolkinocarbonate B (1.10) (6.24 ± 1.08
392 μM, 5.55 ± 0.88 μM, and 2.34 ± 0.67 μM, against EPG85-
393 257P, EPG85-257RNOV, and EPG85-257RDB, respectively)
394 was selected for apoptosis induction studies.
395 Regarding the pancreatic cancer cell lines, the tested
396 compounds were less active (Table 3, Table S3, Supporting
397 Information). Thus, based on IC50 values, only jolkinoate U
398 (1.8) (8.61 ± 0.58 μM against EPP85-181P; 6.63 ± 0.95 μM
399 against EPP85-181RNOV; and 5.86 ± 0.07 μM against EPP85-
400 181RDB) was chosen for further studies.
401 Annexin V/PI Assay and Active Caspase-3 Assay.
402 Jolkinoate L (3) showed a remarkable ability to target both
403 gastric and pancreatic MDR contexts.21 Likewise, jolkinocar-
404 bonate B (1.10) showed interesting results against gastric cells
405 and jolkinoate U (1.8) against pancreatic cells (Table 3, Tables
406 S1 and S2, Supporting Information). Hence, their ability as
407 apoptosis inducers was evaluated. The annexin V/propidium
408 iodide (PI) assay was used to assess if compounds 3, 1.8, and
409 1.10 (30 μM) would induce apoptosis. Caspase activation was
410 measured with the active caspase-3 assays. Detection of these
411 events was performed by ﬂow cytometry after 72 h exposure.
412 The results of total apoptosis (early and late apoptotic events)
413 and caspase-3 activation were expressed as fold increase (ratio
414 between treated samples and untreated samples).
415Jolkinoate L (3), a triﬂuormethylbenzoyl derivative, induced
416apoptosis in the gastric cell lines about 4-fold in EPG85-257P
417and EPG85-257RNOV, and created a statistically signiﬁcant 6-
418 f4fold induction in EPG85-257RDB (Figure 4A). Through the
419caspase-3 data (Figure 4A), it could be concluded that the drug-
420induced cytotoxicity occurred via caspase-mediated apoptosis,
421since there was a caspase-3 activation of 6−9-fold. On the other
422hand, jolkinoate L (3) induced signiﬁcant selective apoptosis in
423the pancreatic MDR phenotypes EPP85-181RNOV and
424EPP85-181RDB, in about 4.5- and 3.5-fold, respectively (Figure
4254B). In the same way as in the gastric cell lines, the apoptotic
426process occurred through caspase-3 activation. Remarkable
427results were found for EPP85-181RNOV, showing a 12-fold
428activation of this apoptosis eﬀector protein (Figure 4B).
429Moreover, jolkinocarbonate B (1.10) showed a statistically
430signiﬁcant apoptosis induction in the gastric EPG85-257RNOV
431cells, but with little apoptosis induction in EPG85-257P or
432EPG85-257RDB (Figure 4C). This selective targeting of
433EPG85-257RNOV cells was corroborated by the caspase-3
434activation data (Figure 4C). Although little apoptosis induction
435was detected for EPG85-257P and EPG85-257RDB cells,
436caspase-3 activation was taking place (Figure 4C). Therefore, a
437quantiﬁable apoptosis induction may occur after 72 h.
438The adamantoyl derivative jolkinoate U (1.8) showed
439statistically signiﬁcant selective apoptosis induction between
440the resistant pancreatic cells (EPP85-181RNOV; EPP85-
441181RDB) and the parental cells; with a 5-fold apoptosis
442induction on EPP85-181RNOV and a 17-fold induction on
443EPP85-181RDB. The observed apoptotic processes were
Figure 4. Induction of apoptosis and activation of caspase-3: (A) jolkinoate L (3) in gastric cells; (B) jolkinoate L (3) in pancreatic cells; (C)
jolkinocarbonate B (1.10) in gastric cells; and (D) jolkinoate U (1.8) in pancreatic cancer cell lines. Total apoptosis was considered the sum of early
and late apoptotic events (cells annexin V positive/PI negative plus cells annexin V positive/PI positive). The results were expressed as the ratio
between treated and untreated samples. Each column represents the mean ± SD (n = 3). Statistical signiﬁcance was calculated for the diﬀerence
between treated resistant cell lines and treated parental cells using a two-tailed unpaired Student’s t test. *, p < 0.05. **, p < 0.01. ***, p < 0.001.
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444 veriﬁed to proceed via caspase-3 activation, as indicated in
445 Figure 4D.
446 ■ EXPERIMENTAL SECTION
447 General Experimental Procedures. See the Supporting
448 Information.
449 General Preparation of Derivatives 1.1−1.10 and 2.1−2.4.
450 The detailed preparation and characterization of the derivatives of
451 jolkinol D (1.1−1.10) and of jolkinodiol (2.1−2.4) can be accessed in
452 the Supporting Information.
453 Rhodamine 123 Accumulation Assay. The mouse T-lymphoma
454 cells L5178Y (ECACC catalogue no. 87111908, U.S. FDA, Silver
455 Spring, MD, USA) and the ABCB1-transfected L5178Y mouse T-
456 lymphoma cells were established and cultured as described.20,38 The
457 cells were resuspended in serum-free McCoy’s 5A medium in 500 μL
458 aliquots adjusted of 2 × 106/mL. The lathyrane derivatives were added
459 at 2 and 20 μM, the positive control verapamil (EGIS Pharmaceuticals
460 PLC, Budapest, Hungary) at 20 μM, and the solvent control DMSO at
461 2% (v/v). The incubation of the samples took place at room
462 temperature for 10 min, after which 10 μL (5.2 μM) of rhodamine-123
463 was added. The samples were washed twice after incubation at 37 °C
464 for 20 min, resuspended in phosphate-buﬀered saline (500 μL), and
465 analyzed by ﬂow cytometry (Partec CyFlow Space instrument, Partec
466 GmbH, Münster, Germany). The histograms were assessed concern-
467 ing the mean ﬂuorescence intensity (FL-1), standard deviation, and
468 peak channel of 20,000 individual cells belonging to the total and gated
469 populations. The ﬂuorescence activity ratio (FAR) was calculated as
470 FAR = (L5178Y-MDRFL ‑1 t r e a t e d/L5178Y-MDRFL ‑1c on t r o l)/
471 (PARFL‑1treated/PARFL‑1control).
472 ATPase Assay. The SB-MDR1 PREADEASY ATPase Kit
473 (SOLVO Biotechnology, Szeged, Hungary) was preformed according
474 to the manufacturer’s instructions. The puriﬁed Sf9 insect membrane
475 vesicles (4 μg protein/well), expressing high levels of human MDR1,
476 were incubated in 50 μL of ATPase assay buﬀer, compound, and 2
477 mM MgATP, for 10 min at 37 °C. The ﬁnal concentration of DMSO
478 in the experiment was 2% (v/v). The ATPase reaction was stopped,
479 and the inorganic phosphate (Pi) production was measured colori-
480 metrically (optical density was read at 630 nm). The amount of Pi
481 produced is proportional to the ABCB1 activity. Hence, ATPase
482 activities were determined as the diﬀerence of the measured Pi
483 liberation with and without the presence of 1.2 mM sodium
484 orthovanadate (vanadate-sensitive ATPase activity). This ATPase kit
485 comprises two diﬀerent tests: the activation and inhibition assays.
486 When the test compound can stimulate the baseline vanadate-sensitive
487 ATPase activity (activation assay), it reﬂects the ABCB1 transported,
488 as is the case of verapamil (40 μM), used as positive control. The
489 inhibition assay assesses the eﬀect of a second transported substrate on
490 ABCB1 ATPase activity. Thus, the compounds are tested in the
491 presence of verapamil (40 μM). Inhibitors of ABCB1 may reduce the
492 verapamil-stimulated vanadate-sensitive ATPase activity. In some
493 cases, inhibitors may inhibit the baseline transporter ATPase activity
494 as well, such as cyclosporine A (40 μM), also used as positive control.
495 Antiproliferative Assay and Drug Combination Studies. The
496 antiproliferative assay was performed according to a published
497 procedure.20 The parental (PAR) and multidrug-resistant (MDR)
498 ABCB1-transfected L5178Y mouse T-lymphoma cells were seeded at 1
499 × 105/mL and incubated with a concentration gradient of compounds
500 (ﬁnal volume of 200 μL/well) for 72 h (5% CO2 at 37 °C). The ﬁnal
501 concentration of DMSO in the experiment was 1% (v/v). Cell growth
502 was determined by measuring the optical density (OD) at 550 nm (ref
503 630 nm) with a Multiscan EX ELISA reader (Thermo Labsystems,
504 Cheshire, WA, USA); and determined as 100 − [(ODsample −
505 ODmediumcontrol)/(ODcellcontrol − ODmediumcontrol)] × 100. Mean IC50
506 values were obtained from three independent experiments for each cell
507 line, by best ﬁtting the dose-dependent inhibition curves in the
508 GraphPadPrism5 program.
509 Drug combinations of doxorubicin (Teva) and the compounds were
510 designed and evaluated according to Chou using the software
511 CalcuSyn Version 2.34,35 Since the optimal concentration range for
512the combination is not known, the most appropriated experimental
513design is by using several concentrations of each agent, with data
514points above and below IC50. The experimental design followed the
515checkerboard microplate method, where dilutions of doxorubicin were
516made in a horizontal direction and the dilutions of resistance modiﬁers
517vertically in a microtiter plate to a ﬁnal volume of 200 μL of medium
518per well. The L5178Y-MDR cells were distributed at 2 × 105 cells/mL
519per well and were incubated for 48 h under standard conditions. The
520cell growth rate was determined after MTT staining, as previously
521described.
20 Each drug combination produces an eﬀect, and constant
522ratios ([compound]/[doxorubicin]) can be taken from the diagonals
523of the checkerboard. The eﬀect of each constant ratio across a
524concentration gradient was computed in CalcuSyn software. More
525details concerning the CalcuSyn model and combination index
526calculation can be assessed in the Supporting Information.
527Collateral Sensitivity Assays: Antiproliferative Assay. Cell
528culture procedures of the human carcinoma cell lines (EPG85-257P
529and EPP85-181P) and their drug-resistant sublines (EPG85-
530257RNOV, EPG85-257RDB, EPP85-181RNOV, EPP85-181RDB)
531have been described previously.
21 Brieﬂy, 5 × 103/mL (EPG85-257P
532and EPP85-181P) and 7.5 × 103/mL (EPG85-257RNOV, EPG85-
533257RDB, EPP85-181RNOV, EPP85-181RDB) were seeded. After
534attachment (48 h), the compounds were added in a dilution series for
535incubation during 5 days (5% CO2 at 37 °C). The ﬁnal concentration
536of DMSO in the experiment was 0.3% (v/v). Cell growth was based on
537sulforhodamine B (SRB) staining and was performed according to a
538published procedure.
21 Cell growth was measured at 562 nm against
539the reference wavelength of 690 nm. Mean IC50 values were obtained
540from three to four independent experiments in triplicate for each cell
541line, by best ﬁtting the dose-dependent inhibition curves in the
542GraphPadPrism5 program. Relative resistance (RR) values were
543calculated as IC50(resistant cells)/IC50(parental cells).
544Annexin V/PI Staining and Active Caspase-3 Assay. An FITC
545Annexin V apoptosis detection kit (BD Pharmingen, BD Biosciences)
546was used to detect cytotoxic drug-induced apoptosis. The intracellular
547presence of active caspase-3 was detected using an FITC Active
548Caspase-3 Apoptosis Kit (BD Pharmingen, BD Biosciences). Both
549assays followed the same experimental design. Brieﬂy, 6 × 104 cell/mL
550of parental cell lines (EPG85-256P and EPP85-181P) and 1 × 105
551cell/mL of resistant cell lines (EPG85-256RNOV, EPG85−256RDB,
552EPP85-181RNOV, and EPP85-181RDB) were seeded in six-well
553plates in complete medium and attached for 24 h. The medium was
554thrown away the next day, and new medium (with 30 μM of
555compounds) was added to the cancer cells. The ﬁnal concentration of
556DMSO in the experiment was 0.3% (v/v). Camptothecin (Cayman
557Chemicals, Ann Arbor, Michigan, USA) was used as positive control
558(1 μM). Cells were further incubated for 72 h (5% CO2, 37 °C). The
559concentration of compounds and positive control, and incubation time
560were optimized in order to ensure a good sampling for ﬂow cytometry
561measurement of the apoptotic process (data not shown). After this
562incubation period, cells were trypsinized, washed in PBS, and stained
563according to each kit manufacturer’s instructions. Stained cells were
564analyzed using a BD Accuri C6 ﬂow cytometer (BD Pharmingen, BD
565Biosciences), and data were processed with BD Accuri C6 software.
566Each sample was assessed using a collection of 10 000 events. The
567mean values and standard deviations were calculated from three
568independent experiments.
569Statistical Analysis. K-means clustering, which subdivides the
570compounds (those with the nearest mean) into groups that exhibit a
571high degree of similarity, was performed with Tanagra, version 1.4.41
572(https://eric.univ-lyon2.fr/~ricco/tanagra/). Statistical evaluation of
573the apoptosis assays data was performed with the two-tailed unpaired
574Student’s t test using GraphPadPrism5 software. Probability value p <
5750.05 was considered statistically signiﬁcant.
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